Crestor (Rosuvastatin) FDA Prescribing Info & Approval Status
FDA approved Crestor on August 12, 2003 (NDA 021366) for hyperlipidemia. Covers doses, black box warning, generics since 2016, and global approvals.
Rosuvastatin: Regulatory History
5 source-based articles maintained by the HealthRX.com Editorial Team.
5articles
3topic areas covered
Jan 15, 2025latest review
Rosuvastatin: Regulatory History library
Showing 5 of 5 clinical reviews.
Crestor EMA vs FDA Approach: How Rosuvastatin Regulation Differs Across the Atlantic
A detailed comparison of how the FDA and EMA regulate rosuvastatin (Crestor), including approval timelines, label differences, post-market safety monitoring, and clinical implications for prescribers.
Crestor Label Updates 2020-2026: What Changed
FDA revised the Crestor (rosuvastatin) label six times since 2020, adding interaction warnings, new renal dosing limits, and updated myopathy risk language.
Crestor Legal & Patent Challenges: Rosuvastatin's Regulatory History
A regulatory history of Crestor (rosuvastatin), covering FDA approval, Paragraph IV patent litigation, generic entry, safety label updates, and the JUPITER-driven indication expansion, with a framework for separating legal disputes from safety findings.
Crestor Pipeline and Next-Gen: Rosuvastatin Regulatory History, Label Updates, and What Comes Next
A regulatory overview of rosuvastatin (Crestor), covering FDA approval history, major label changes, post-market safety monitoring, generic entry, and where next-generation lipid-lowering drugs fit alongside it.